volume 2, issue 8, PS468 2007
DOI: 10.1097/01.jto.0000283415.19240.46
View full text
|
|
Share

Abstract: S468with advanced NSCLC. Vandetanib targets clinically validated signaling pathways in NSCLC by inhibiting VEGFR-dependent tumor angiogenesis and EGFR-dependent tumor growth and survival. Vandetanib also inhibits RET kinase activity, which is an important growth driver in certain types of thyroid cancer. Phase I evaluation in patients with advanced solid tumors showed vandetanib was generally well tolerated at daily oral doses of ≤300 mg. Common adverse events included rash, diarrhea and asymptomatic QTc prolo…

Expand abstract

Search citation statements

Order By: Relevance

Citation Types

0
6
0

Paper Sections

0
0
0
0
0

Publication Types

0
0
0
0

Relationship

0
0

Authors

Journals